5:15 PM – 6:45 PM  Exhibit Hall (220C)

Presenters of featured posters will be present during poster tours to explain their work. Tours take place at the end of the day on Tuesday and Wednesday. Tour sign-up required (see sheets in front of main entrance to Exhibit Hall at 220D). Meeting point at first poster of tour at 5:15 PM.

**Poster Tour W1**

**Guide:** Matthew Farrer (USA)

- **P01.01** Calmodulin regulation of L-type calcium channels in SNc DA neuron culture
- **P01.05** Dietary administration of paraquat for 13 weeks does not result in a loss of dopaminergic neurones in the substantia nigra of mice
- **P01.13** Role of MAPT variation in Parkinsonian disorders
- **P01.14** Exome sequencing of Norwegian families with PD reveals novel gene mutations
- **P01.18** Households organophosphorus pesticide use and Parkinson’s disease
- **P01.20** Exploring the impact of Parkinson disease (PD) susceptibility loci in older persons without PD
- **P01.21** The complex interaction of LRRK2 with the cytoskeleton

**Poster Tour W2**

**Guide:** Ted Dawson

- **P03.03** Protein misfolding cyclic amplification (PMCA) as an alpha-synuclein anti-aggregation drug-screening tool
- **P03.05** Smoking and Parkinson’s disease: nicotine binds to alpha-synuclein and causes large conformational changes which may prevent it from misfolding
- **P03.06** 14-3-3 chaperone protein modulates alpha-Synuclein aggregation and toxicity
- **P04.04** The role of intramolecular interactions in parkin activation in vivo
- **P04.11** Mutant LRRK2 expression induces calcium dysregulation and dendritic mitophagy
- **P05.02** High Cortical LB burden and Aβ pathology in Lewy Body Dementia and Parkinson’s disease Dementia
- **LBP05** Tau oligomers as novel therapeutic target for PD and neurodegenerativesynucleinopathies

**Poster Tour W3**

**Guide:** Etienne Hirsch

- **P09.01** Neuroprotection and neurorescue properties of Sitagliptin in 6-hydroxydopamineronotent model of Parkinson’s disease
- **P09.03** The effect of a chronic treatment with MPEP, an mGlu5 receptor antagonist, on brain basal ganglia D1/D2 receptors, preproenkephalin/preprodynorphin mRNA levels and ERK/Akt signaling pathways in de novo parkinsonian monkeys
- **P10.01** A functional magnetic resonance imaging approach towards understanding thecircuit-level effects of deep brain stimulation
- **P10.03** Quantitative evaluation of hypokinesia in Parkinson’s disease using sensor gloves
- **P11.01** Dose-dependent therapeutic effects of FK506 on dopaminergic neurodegenerationand neuroinflammation in a viral vector-based alpha-synuclein rat model for Parkinson’s disease
- **P11.07** Unilateral 6-OHDA lesion and Dopa administration in Nur77 knockout rats reveal an important role of this transcription factor in Parkinson’s disease and its treatment
- **P11.08** Selective knockout of the vesicular GABA transporter (VGAT) in the motor cortexcompletely protects against MPTP-induced lesioning in mice

**Poster Tour W4**

**Guide:** Alice Templin

- **P28.08** Tai Chi, zumba, drumming and golf: an integrative approach to promote PDwellness
- **P28.16** Effects of resistance training on bradykinesia, functional performance and disease severity in individuals with Parkinson’s disease
- **P28.17** Development of a community-based Nordic walking program for persons with Parkinson’s disease
- **P29.04** Comparative biomechanics from ice skating and regular terrain locomotion amongst people living with Parkinson’s disease
- **P29.11** School ‘Health’ in the lives of patients with Parkinson’s disease
- **P32.02** Shared decision making in current treatment choice in advanced Parkinson’s disease
- **P32.03** Equal options: shared decision? Development of a decision aid for treatment choice in advanced Parkinson’s disease
Poster Tour W5

Guide: Anne-Louise Lafontaine

- P34.03 Developing a network of interdisciplinary Parkinson's rehabilitation teams in nontraditional settings: providing high-quality treatment to populations underserved settings
- P34.04 The relationship between patient age and resource utilization among newly diagnosed Parkinson's disease patients
- P34.05 Our experience developing a service for in-patients with Parkinson's
- P34.07 Does a specialist Parkinson's unit improve outcomes for hospitalised Parkinson's patients?
- P37.01 Multidisciplinary care in professional networks for Parkinson's disease

Poster Tour W6

Guide: Michel Panisset

- P12.09 Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020)
- P12.22 Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease
- P13.05 Motor, cognitive and affective characteristics of new-fallers compared to non-fallers in an incident cohort of Parkinson's disease
- P13.06 Gait predicts decline in attention over 18 months in an incident cohort of Parkinson's disease
- P14.05 The Relation between Obsessive Compulsive Behaviors and PARKIN Genotype
- LBP14 The clinical features of asymptomatic, first degree relatives of Ashkenazi Jewish Parkinson patients, carriers of the G2019S mutation in the LRRK2 gene

Poster Tour W7

Guide: Daniel Weintraub

- P15.01 Personality and depression: Factors that influence reported quality of life among PD patients
- P15.02 Impact of Parkinson's disease on social role function: Multi-faceted disability
- P15.03 A new paradigm in neuropsychological assessment: Motor Imagery. A pilot Study with Parkinson's disease patients
- P15.19 Vitamin D in Parkinson's disease
- P16.03 High intensity exercise improves skeletal muscle mitochondrial function corresponding with reduced fatigability in Parkinson's disease
- P16.04 Treatment of obstructive sleep apnea with continuous positive airway pressure improves non-motor symptoms in Parkinson's disease patients
- P16.05 Focus Group and Quantitative Assessment of Sleep and Fatigue in Patients with Parkinson's Disease
- LBP19 The Roles of Dorsal and Ventral Striatum in Stimulus-Response Learning: Implications for Parkinson's Disease

Poster Tour W8

Guide: Anthony Lang

- P20.01 Changes in troublesome dyskinesia and its relationship with dose in advanced Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion
- P20.03 Taq1A polymorphism improves Dopamine Agonist therapeutic response in Parkinson's Disease
- P20.07 Effects of levodopa on gait variability of backward walking in Parkinson's disease
- P20.12 Safety analyses from open-label clinical trials of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Events not related to device or procedure
- P20.13 Effective treatment of Parkinson tremor using kinematics to optimize Botulinum neurotoxin type A injection
- P20.23 Pharmaceutical Quality of Seven generic Levodopa/Benserazide Products compared with original Madopar® / Prolopa®
Poster Tour W9

Guide: Margarita Makoutonina

P22.31 AmbuloSono: a sensorimotor contingent musical walking program for people living with Parkinson’s disease
P22.50 Neurocognitive rehabilitation with motor imagery vs treadmill training for freezing of gait in Parkinson’s disease. A randomized controlled study
P22.61 A unique community Group Rehabilitative Exercise and Therapy (GREAT) program for people with Parkinson’s disease
P22.68 The effectiveness of occupational therapy in Parkinson’s disease
LBP24 The effect of dopaminergic medication on muscle performance in people with Parkinson’s disease-related fatigue
LBP25 The role of optic flow on locomotion in young adults during overground walking
LBP27 Central components of quadriceps fatigue are dopamine dependent

Poster Tour W10

Guide: Terry Ellis

P22.01 Impact of freezing of gait on self-perceived balance confidence for functional activities in people with Parkinson’s disease
P22.17 Treatment effects of Attention Process Training for an individual with Parkinson’s disease: A single-subject study
P22.29 The impact of high intensity exercise on outcome in people with Parkinson’s disease: A systematic review
P22.48 The type of secondary task matters in dual task walking during the Timed Up and Go
P22.49 Pre-stepping postural preparation in patients with Parkinson’s disease with and without freezing of gait
P22.51 Assessment of gait therapy effectiveness in the patients with Parkinson’s disease on the basis of three-dimensional movement analysis
P22.54 Home-based gait improvement in Parkinson’s disease: using video to support self-cueing

Poster Tour W11

Guide: Jon Stamford

P24.04 Initial choice of dopaminergic therapy in the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Longitudinal Study-1 (LS-1)
P24.06 Apokyn for morning akinesia trial (AM IMPAKT)
P24.11 A cohort study of Parkinson’s disease in British Columbia
P24.12 Efficacy, safety and tolerability of rasagiline as add-on to suboptimal dopamine agonist monotherapy in Parkinson’s disease (PD): The ANDANTE study
P24.14 Effects of a community-based balance program on enhancing the balance performance in people with Parkinson’s disease
P24.16 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Poster Tour W12

Guide: Hayley Carpenter

P38.01 The chain that bonds not binds – a project in awareness
P38.07 Pass the baton for Parkinson’s awareness and fundraising program
P38.19 The social movement: building the More Than Motion™ Facebook community for people living with Parkinson’s disease
P39.02 The effect of Medicare Part D on Parkinson’s disease patients: a four year retrospective study
P39.03 The accomplishments and challenges of international Parkinson advocacy: social history, literature review and call to action
P39.04 Policy Advocacy on Parkinson’s Diseases in Nepal
P41.03 Parkinson’s UK Research Support Network – working together to find a cure
**Poster Tour T1**

**Guide:** Louis Tan  

P01.02 Analysis of Gene Expression in Peripheral Blood of Patients with Parkinson’s Disease  

P01.10 COMT × DRD4 epistasis impacts cognitive flexibility during the Trail Making Test  

P01.11 PARK18 SNP is Associated with Differential Expression of Major Histocompatibility complex II in Healthy Controls and Parkinson’s Disease Patients  

P01.16 Investigation of PD brain DNA for SNCA (alpha-synuclein) mutations, and cellular studies of the recently reported H5OQ  

P01.17 Revisiting Smoking and Parkinson’s: Marker, Cause or Effect?  

P01.22 Identification of LRRK2 G2019S modifiers of disease penetrance  

P02.16 Lewy body fractions from patients with Parkinson’s disease initiate-synuclein-dependent neurodegeneration in mice and non-human primates

**Poster Tour T2**

**Guide:** Jeffrey Kordower

P06.02 Identification of cis- and trans-regulatory elements and signaling pathways imparkin gene expression — A genomic fugu parkin model  

P06.03 Molecular mechanisms of neurodegeneration in the En1+/− mouse model of Parkinson’s disease  

P06.05 A reverse engineered Parkinson’s disease gene regulatory network identifies RGS2as a direct modulator of LRRK2 activity  

P06.08 Synergistic effects of mGluR5 antagonism and 5-HT1A/1B agonism in a rat model of L-DOPA-induced dyskinesia  

P06.13 Longitudinal in vivo imaging in a novel model of Parkinson’s disease in minipig  

P06.18 Parkinsonian features in aging GFAP.HMOX1 transgenic mice overexpressing humanHO-1 in the astroglial compartment  

P06.24 LRRK2 G2019S knock in Mice display progressive alterations in dopamine releaseand metabolism  

LBP11 Striatal and extrastriatal dopamine correlates with cognition in Lewy body disorders: an 11C altropane PET study

**Poster Tour T3**

**Guide:** Mark Guttmann

P28.04 In the Clinic, in Education and in the Community: A Capacity Building Strategy for Comprehensive Supportive Services and Wellness Programs through CommunityPartnership  

P28.06 Community wellness for people with Parkinson’s  

P28.07 Nutritional status correlates with non-motor and motor symptoms of Parkinson’s disease: A cross-sectional analysis in 143 patients  

P28.09 A continuous care model: education to rehabilitation to wellness  

P28.12 Improving nutritional status in Parkinson’s disease and the effects on Parkinson’s disease symptoms

**Poster Tour T4**

**Guide:** Lucie Lachance

P30.02 Awareness of Parkinson’s Disease Questionnaire (APDQ) in an Urban Asian setting  

P31.01 The impact of clinical symptoms on quality of life in patients with advancedstage Parkinson’s disease  

P31.04 The Parkinson Atlas: transparency in medical practice variations in PD care in the Netherlands  

P31.05 Comparison of the psychological symptoms and disease-specific quality of life (QoL) between early- versus late-onset Parkinson’s disease patients  

P31.08 Factors, disabling patients on the early stages of Parkinson’s disease  

P31.12 Does home-visiting improve quality of life of those living with Parkinson’s disease living in rural areas? – a program evaluation  

P31.14 Patient-centered care in the Parkinson centers of excellence: a multicenter study
**Poster Tour T5**

**Guide:** Ruth Hagestuen

- P36.07 An evaluation of the Occupational Therapy Memory Group run for those with mild cognitive impairment in Parkinson's Disease
- P36.08 Applying Integrated Chronic Care Management model using LSVT BIG and LSVT LOUD protocol framework for care of people with PD in the home
- P36.09 Twenty-five years of discovery: A longitudinal study of Parkinson support groups
- P36.10 The effect of a music cue on gait and quality of life in Parkinson’s: a case study
- P36.12 Home-based training with Nintendo Wii Fit and Balance Board in Parkinson’s disease. Is it a tool for self-management motor activities in long term care?
- P36.16 Expressive Writing Improves Psychosocial Functioning of Patients with Parkinson’s Disease and their Caregivers

**Poster Tour T6**

**Guide:** Laura Marsh

- P15.07 The impact of treatment response to cognitive-behavioral therapy on different clusters of depressive symptoms in Parkinson’s disease
- P15.09 Mild Cognitive Impairment in Parkinson’s Disease is linked with Extensive Cortical Thinning during Longitudinal Analysis
- P15.11 Initial Results of a Clinical Trial comparing a Neurocognitive Intervention to Supportive Therapy in Individuals with Parkinson’s Disease
- P15.12 Does rTMS enhance memory retention in Parkinson’s Disease (PD)?
- P15.13 Working memory and facial expression recognition in Parkinson’s disease individuals
- P15.16 Exercise for the mind: Investigating the effects of exercise on cognition in Parkinson’s disease
- LBP20 Associations of Cognitive Domain Impairments and Gait in Parkinson’s Disease

**Poster Tour T7**

**Guide:** Thomas Gasser

- P19.02 Effect of Dopamine Receptor Binding Agents on Dopamine Transporter (DaT) Scan Result
- P19.03 A large Turkish Parkinson Pedigree with alpha-Synuclein Duplication: Blood Expression Biomarkers elucidate predictive Diagnostics and Pathway
- P19.04 A Novel Blood-Brain Barrier Permeable PET Ligand for Parkinson’s Disease
- P19.05 Longitudinal striatal atrophy during Parkinson’s progression
- P19.07 Metabolomic changes associated L-DOPA induced dyskinesia in a MPTP primate model of Parkinson’s disease and the effect of DHA or plasmalogens precursor administration
- P19.17 Influence of Dopamine Transporter (DaT) scan on medical management in movement disorders specialists: Cleveland Clinic experience

**Poster Tour T8**

**Guide:** Roger Barker

- P17.08 Targeted next-generation sequencing for Parkinson’s disease
- P21.02 Case report: transplantation of fetal porcine ventral mesencephalic cells (FPVMC) for Parkinson’s disease (PD): results and pathology
- P21.04 Long-term safety considerations of deep brain stimulation in treatment of Parkinson’s disease
- P21.08 Modulation of glutamate receptors in dyskinetic MPTP monkeys receiving unilateral subthalamotomy
- P21.15 Social support and motor outcomes after Deep Brain Stimulation in patients with Parkinson’s Disease
Poster Tour T9

Guide: Bastiaan Bloem

P22.10 A novel approach to testing freezing of gait in patients with Parkinson’s disease: The clover test
P22.32 Using the SpeechVive to treat speech impairments in Parkinson’s disease
P22.47 Changes in vowel (co)articulation following intensive voice treatment (LSVT) in Parkinson’s disease
P22.55 The impact of physical environmental barriers on accessibility problems—very old people with self-reported Parkinson’s disease versus controls
P22.59 Efficacy of mental practice mnemonic coupled with physical practice in improving gait of patients with Parkinson’s disease
P22.65 Development of an intelligent bicycle for rehabilitation in Parkinson’s disease
LBP26 Long-term Observation of Speech and Language in Patients with Parkinson’s Disease under Continuous Levodopa/Carbidopa Intestinal Gel Therapy

Poster Tour T10

Guide: Marten Munneke

P22.21 Benefits of task-specific learning-principled practice to improve freezing of gait for individuals with Parkinson disease in a small group community setting. A case series study
P22.34 European physiotherapy guidelines for people with Parkinson’s disease
P22.44 Test-retest and inter-rater reliability of the mini-BESTest in mild to moderate Parkinson’s disease – a clinical approach
P22.46 An acute Parkinson’s therapy pathway: bridging the gap between hospital and home
P22.60 A vision of improved postural stability in Parkinson’s disease: enhancing balance through visual training under dual-task conditions
P23.02 Nicotine and nicotinic receptor drugs reduce L-dopa-induced dyskinesias in an nonhuman primate model of Parkinson’s disease

Poster Tour T11

Guide: Sara Riggare

P25.01 3D Sensors, the New Paradigm for Assessing Movement Disorders
P25.04 Can single-leg stance time be used to assess bilateral progression of Parkinson’s disease?
P25.06 Dual-task performance assessment (DTPA): A novel test for assessing motor and cognitive performance during dual-task
P25.08 Measures of quality care reveal large variation across NPF Centers of Excellence
P26.07 SENSE-PARK: measuring Parkinson in the home environment in an objective, continuous and minimally obtrusive fashion

Poster Tour T12

Guide: Israel Robledo

P40.02 Managing Parkinson’s disease symptoms while hospitalized for non-PD related conditions
P42.01 Experiencing Parkinson’s Disease and the Reward System: the point of view of an informed patient
P42.03 Not only an old person’s disease
P42.04 How the nonprofit sector can help people living with Parkinson’s receive quality voice treatment: two successful models
P42.08 Clinical profile of Parkinson’s disease patients with pneumonia
P42.09 The effect of STN-DBS’s laterality on voice and perception of speech intelligibility of patients with Parkinson’s disease
P42.11 ParkNC: a referral network for enhanced Parkinson’s disease care throughout North Carolina
LBP32 Achieving the impossible together